Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Advances in Radiation Oncology|October 14, 2021
Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell CarcinomaJonathan E Schoenhals, Osama Mohamad, Alana Christie, et al.
Urologic Oncology|February 11, 2022
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombusYuval Freifeld, Ivan Pedrosa, Mark Mclaughlin, et al.
European Urology Focus|June 29, 2019
The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisRohann J M Correa, Alexander V Louie, Nicholas G Zaorsky, et al.
International Journal of Radiation Oncology, Biology, Physics|January 24, 2026
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma treated with Stereotactic Ablative RadiotherapyAneesh Dhar, Shankar Siva, Vivian S Tan, et al.
Advances in Radiation Oncology|September 22, 2025
Extracranial Palliative Radiation Therapy for Renal Cell CarcinomaYoung Suk Kwon, Eric Hsu, Maggie Stein, et al.
Clinical Genitourinary Cancer|December 28, 2025
Real-World Treatment Outcomes in Patients With Ga68-PSMA-PET Positive Metastatic Hormone-Sensitive Prostate Cancer With or Without Conventional Imaging CorrelatesWadih Issa, Maureen Aliru, Song Zhang, et al.
Oncoimmunology|June 15, 2018
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapyOsama Mohamad, Alberto Diaz de Leon, Samuel Schroeder, et al.
Technology in Cancer Research & Treatment|August 11, 2025
Expanding SCINTIX Biology-Guided Radiotherapy Beyond Lung and Bone: A Planning Feasibility and Dosimetric Study on the RefleXion X1 SystemHaozhao Zhang, Grant Gibbard, Chenyang Shen, et al.
Translational Oncology|June 7, 2023
Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitorsVatsala Mundra, Yuqiu Yang, Mitchell S von Itzstein, et al.
The Journal of Clinical Investigation|January 17, 2018
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regressionHaidong Tang, Yong Liang, Robert A Anders, et al.
Pageof 11